Efficacy and safety analysis of atorvastatin calcium combined with ezetimibe in the treatment of coronary heart disease
Objective To analyze the effect and safety of atorvastatin calcium combined with ezetimibe in the treatment of coronary heart disease.Methods 76 patients with coronary heart disease were divided into a study group and a control group according to different treatment methods,each with 38 cases.The control group was treated with atorvastatin calcium alone,and the study group was treated with atorvastatin calcium combined with ezetimibe.Both groups were compared in terms of treatment effect,blood lipid indexes[total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDL-C)and low density lipoprotein cholesterol(LDL-C)]before and after treatment,and the occurrence of adverse reactions,levels of oxidative stress indexes[malondialdehyde(MDA),superoxide dismutase(SOD),myeloperoxidase(MPO)]before and after treatment.Results After treatment,the total effective rate of the study group was 94.74%,which was significantly higher than the control group's 76.32%(P<0.05).After treatment,the levels of TC,LDL-C and TG in both groups were lower than those before treatment,and the level of HDL-C was higher than that before treatment;the study group had TC of(2.15±0.33)mmol/L,LDL-C of(1.46±0.29)mmol/L and TG of(1.12±0.05)mmol/L,which were lower than(3.72±0.26),(2.07±0.31)and(1.48±0.04)mmol/L in the control group;the study group had higher HDL-C of(1.43±0.06)mmol/L than(1.18±0.05)mmol/L in the control group;the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was a little lower than that in the control group,but the difference was not statistically significant(P>0.05).After treatment,SOD in both groups was higher than that before treatment,and MDA and MPO were lower than those before treatment;the study group had higher SOD of(323.38±40.57)U/L than(297.96±39.65)U/L in the control group;the study group had MDA of(4.67±0.48)μmol/L and MPO of(93.82±1.01)ng/ml,which were lower than(6.45±0.69)μmol/L and(95.57±1.38)ng/ml in the control group;the difference was statistically significant(P<0.05).Conclusion In the clinical treatment of coronary heart disease,atorvastatin calcium combined with ezetimibe has a more obvious effect,and there will be no serious adverse reactions after the combined use of the drug,so it has a high safety.
万方数据
维普
